{Reference Type}: Journal Article
{Title}: Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.
{Author}: Melmed S;Casanueva FF;Hoffman AR;Kleinberg DL;Montori VM;Schlechte JA;Wass JA; ;
{Journal}: J Clin Endocrinol Metab
{Volume}: 96
{Issue}: 2
{Year}: Feb 2011
{Factor}: 6.134
{DOI}: 10.1210/jc.2010-1692
{Abstract}: <B>OBJECTIVE: </B>The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia.<BR><B>METHODS: </B>The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer.<BR><B>METHODS: </B>This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence.<BR><B>METHODS: </B>One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines.<BR><B>CONCLUSIONS: </B>Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.